Table 3.

Measures Of Association (OR/HR) And 95% Confidence Intervals (CI) For Plasma Endostatin With The Kidney Function Decline Outcome Modeled Categorically And Continuously

ACCORD	Model 1 (95% CI)	OR		Model 2 (95% CI)	OR		Model 3 (95% CI)	OR		Model 4 (95% CI)	OR
Plasma Endostatin in ng/ml
OR per 1-unit log2 increase	2.6 (1.7 – 4.4)		2.6 (1.6 – 4.4)			2.5 (1.5 – 4.1)			2.5 (1.4 – 4.3)
<=32.3 ng/ml	1 (Ref)		1 (Ref)			1 (Ref)			1 (Ref)
32.4–38.2 ng/ml	1.7 (0.9 – 3.1)		1.7 (0.9 – 3.2)			1.7 (0.9 – 3.4)			1.7 (0.9 – 3.4)
38.3–47.6 ng/ml	3.0 (1.6 – 5.4)		2.8 (1.5 – 5.3)			2.9 (1.5 – 5.7)			3.1 (1.5 – 6.1)
>47.7 ng/ml	3.6 (2.0 – 6.7)		3.6 (1.9 – 6.8)			3.6 (1.8 – 7.1)			3.6 (1.8 – 7.3)
BioMe	Model 1 (95% CI)	HR	Model 2 (95% CI)		HR	Model 3 (95% CI)		HR	Model 4 (95% CI)		HR
Plasma Endostatin in ng/ml
HR per 1-unit log2 increase	3.0 (2.1 – 4.1)		2.9 (2.1 – 4.1)			2.9 (2.1 – 4.1)			2.6 (1.8 – 3.8)
≤30.5 ng/ml	1 (Ref)		1 (Ref)			1 (Ref)			1 (Ref)
30.6 – 38.7 ng/ml	1.6 (0.9 – 3.1)		1.9 (0.9 – 3.7)			1.9 (0.9 – 3.7)			1.8 (0.9 – 3.5)
38.7 – 48.6 ng/ml	2.1 (1.1 – 3.9)		2.2 (1.1 – 4.3)			2.2 (1.1 – 4.3)			2.1 (1.0 – 4.1)
≥48.7 ng/ml	4.7 (2.7 – 8.4)		5.1 (2.7 – 9.6)			5.1 (2.7 – 9.6)			4.4 (2.3 – 8.5)

In ACCORD

Model 1: Unadjusted conditional Logistic Model; Model 2: Model 1 + Cardiovascular risk factors (HbA1c; mean arterial pressure; history of cardiovascular disease, hypertension and heart failure; BMI; intensive glycemic control arm, intensive blood pressure control arm); Model 3: Model 2 + Medications (Fibrate arm, ACE-Inhibitors/Angiotensin Receptor Blocker usage); Model 4: Model 3 + baseline eGFR and UACR.

In BioMe

Model 1: Unadjusted cox regression Model; Model 2: Model 1 + Age, sex, cardiovascular risk factors (HbA1c; mean arterial pressure; history of cardiovascular disease, hypertension and heart failure; BMI); Model 3: Model 2 + Medications (ACE-Inhibitors/Angiotensin Receptor Blocker usage); Model 4: Model 3 + baseline eGFR.